XML 36 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment, Customer and Geographic Information
6 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Segment, Customer and Geographic Information

Note 13. Segment, Customer and Geographic Information

The Company continues to operate in only one segment, blood safety. The Company’s chief executive officer is the chief operating decision maker who evaluates performance based on the net revenues and operating loss of the blood safety segment. The Company considers the sale of all of its INTERCEPT Blood System products to be similar in nature and function, and any revenue earned from services is minimal.

The Company’s operations outside of the U.S. include a wholly-owned subsidiary headquartered in Europe. The Company’s operations in the U.S. are responsible for the R&D and global and domestic commercialization of the INTERCEPT Blood System, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, the Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.

The Company had the following significant customers that accounted for more than 10% of the Company’s total product revenue, each of which operates in a country outside of the U.S., during the three and six months ended June 30, 2017 and 2016 (in percentages):

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

 

June 30,

 

 

 

2017

 

 

2016

 

2017

 

2016

 

EFS

 

 

13%

 

 

*

 

*

 

*

 

Advanced Technology Comp. KSC

 

 

10%

 

 

*

 

*

 

*

 

Rode Kruis Vlaanderen

 

 

10%

 

 

*

 

*

 

 

10%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*   Represents an amount less than 10% of product revenue.